Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases

HIGHLIGHTS
- CypA inhibition or knockdown blocks breast cancer cell signaling, growth, and migration
- NIM811 inhibited PRL-induced genes and gene pathways relevant to cancer signaling
- Deletion of CypA has shown reduction in tumorigenesis and metastasis in mice
Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases

Shawn Hakim, Justin M. Craig, Jennifer E. Koblinski, and Charles V. Clevenger

SUMMARY
Prolactin (PRL) and its receptor (PRLr) play important roles in the pathogenesis of breast cancer. Cyclophilin A (CypA) is a cis-trans peptidyl-prolyl isomerase (PPI) that is constitutively associated with the PRLr and facilitates the activation of the tyrosine kinase Jak2. Treatment with the non-immunosuppressive prolyl isomerase inhibitor NIM811 or CypA short hairpin RNA inhibited PRL-stimulated signaling, breast cancer cell growth, and migration. Transcriptomic analysis revealed that NIM811 inhibited two-thirds of the top 50 PRL-induced genes and a reduction in gene pathways associated with cancer cell signaling. In vivo treatment of NIM811 in a TNBC xenograft lessened primary tumor growth and induced central tumor necrosis. Deletion of CypA in the MMTV-PyMT mouse model demonstrated inhibition of tumorigenesis with significant reduction in lung and lymph node metastasis. The regulation of PRLr/Jak2-mediated biology by NIM811 demonstrates that a non-immunosuppressive prolyl isomerase inhibitor can function as a potential breast cancer therapeutic.

INTRODUCTION
Cyclophilins are highly conserved proteins throughout evolution (Wang and Heitman, 2005). Cyclophilin A (CypA) is involved in protein folding, trafficking, receptor assembly, cell cycle regulation, and signal transduction (Lammers et al., 2010). CypA is part of the peptidyl-prolyl isomerase (PPI) family of enzymes that catalyzes the cis-trans interconversion of imide bonds of proline residues inducing protein backbone conformational change (Gothel and Marahiel, 1999) and was initially identified as a binding partner of cyclosporine (CsA), an immunosuppressive drug (Handschumacher et al., 1984). The CypA-CsA complex allosterically inhibits calcineurin preventing IL2-mediated T cell activation (Roehrl et al., 2004). CypA is aberrantly expressed in cancer cells including the breast, lung, and pancreas (Lee and Kim, 2010). Female allograft recipients treated with CsA demonstrated a 50% reduction in incidence of breast cancer after 10 years (Stewart et al., 1995), suggesting a chemopreventive role for this agent within the breast. A potential target for CsA within the breast is the prolactin receptor (PRLr), as CypA constitutively interacts with this receptor (Clevenger et al., 2003; Zheng et al., 2008).

The polypeptide hormone prolactin has been implicated in the pathogenesis of breast cancer based on data at the cellular, epidemiologic, and genetic levels (Clevenger and Kline, 2001). PRL binds and signals through its cognate receptor at the cell surface of normal and breast tissue (Gertler et al., 1996). Breast cancer cells produce PRL, which contributes to increased proliferation, survival, motility, and invasion of breast cancer cells in vitro (Perks et al., 2004). In turn, its cognate receptor, PRLr, is expressed in 98% of human breast cancers based on immunohistochemistry, in situ hybridization, and qRT-PCR analysis (Mertani et al., 1998). Mice that overexpressed PRL developed both ER+ and ER- tumors at both endocrine and autocrine/paracrine levels (Clevenger et al., 2003). In contrast, PRL knockout mice show significantly increased latency in developing oncogene-driven mammary tumors (Kelly et al., 2001). In vitro, PRLr knockdown impairs anchorage dependent and independent growth in breast cancer cells (Fiorillo et al., 2013).

Like growth hormone, PRL binding initiates a conformational change in the pre-dimerized PRL receptor (Gadd and Clevenger, 2006). The conformational change in the receptor leads to activation of tyrosine kinases like Janus kinase 2 (Jak2) and Src, which rapidly phosphorylate the C terminus of the PRLr (DaSilva et al., 1994), and these receptor proximal events enhance the activation of signaling pathways (Syed et al., 2003). Jak2 is
constitutively associated with the PRLr, and PRL binding to the receptor leads to the auto-phosphorylation of Jak2 (Leonard and O’Shea, 1998). Auto-phosphorylated Jak2 in turn phosphorylates C-terminal PRLr residues, enabling Stat5 recruitment and tyrosine phosphorylation (Levy and Darnell, 2002). Tyrosine-phosphorylated Stat5 (Signal Transducer and Activator of Transcription 5) then dimerizes, translocates to the nucleus, and activates transcription of PRL-responsive gene like cyclin D1 and CISH (Brockman and Schuler, 2005; Schindler et al., 1992). Conditional loss of either Jak2 or Stat5 results in a lactation-deficient phenotype that closely mimics the PRLr knockout mouse model (Wagner et al., 2004). Thus the functions of the PRLr, Jak2, and Stat5 are closely associated with breast development and pathogenesis.

Previous studies from our laboratory found that the PPI activity of CypA contributes to PRLr and Jak2 function (Zheng et al., 2008). PRL-mediated signaling/gene expression is directly correlated with levels of CypA, and specifically its PPI activity. Furthermore, overexpression of a CypA interaction-defective PRLr mutant (P334A), was shown to significantly downregulate PRLr/Jak2-mediated signaling (Zheng et al., 2008). Pharmacologically, inhibition of CypA by the immunosuppressive prolyl isomerase inhibitor CsA blocks Jak2/Stat5 phosphorylation and growth/metastasis of ER−/+ breast cancer xenografts (Zheng et al., 2008). The use of immunosuppressive CsA in breast cancer is problematic, however, and its use can only be envisaged in the metastatic setting. Here, we sought to test the non-immunosuppressive CypA inhibitor, N-methyl-4-isoleucine-cyclosporine (NIM811), as well as the in vivo effect of CypA loss of function when introduced into a spontaneous mouse mammary cancer model. The introduction of a single side chain to the CsA backbone renders NIM811 non-immunosuppressive and virtually non-toxic, as was seen in a recent clinical trial (Lawitz et al., 2011). These studies found that non-immunosuppressive NIM811 was equipotent to CsA, resulting in significant inhibition of PRL-driven signaling, in vitro growth, and in vivo metastases in mouse models of breast cancer. Overall, these results reveal that this isomerase can be inhibited by a non-immunosuppressive PPI inhibitor and is a potential target for the therapeutic intervention of breast cancer metastasis.

RESULTS
NIM811 Inhibits Phosphorylation of PRLr-Stat5 Signaling Intermediates

Based on recent studies, CypA has found to be a constitutively interacting protein with the PRLr (Leonard and O’Shea, 1998; Zheng et al., 2008). Inhibition of CypA activity with immunosuppressive PPI inhibitor CsA in breast cancer cells blocked PRLr signaling, as well as Jak2 and Stat5 phosphorylation (Zheng et al., 2008). CsA is a potent inhibitor of CypA and capable of modulating breast cancer functions but remains an immunosuppressive agent with toxic side effects. Therefore, the action of a non-immunosuppressive and non-toxic analog of CsA, termed NIM811, was explored.

Phospho-specific anti-PRLr, Jak2, and Src antibodies were utilized to test the effects of NIM811 on the PRL-induced phosphorylation given their significance to PRL-associated signaling. To that end, ER/PR+ T47D breast cancer cells were pre-treated with NIM811 and then stimulated as a function of time with PRL. NIM811 significantly decreased tyrosine-phosphorylation of PRLr, Jak2, Src, and Stat5 (Figures 1A and 1B). There was a marked increase in pJak2-Y1007/1008 within 7.5–15 min following PRL stimulation; however, a 3- to 5-fold inhibition of pYJak2 was observed with NIM811 treatment as a function of time (Figure 1), confirming the importance of CypA-PPI activity regulating Jak2 activation in breast cancer cells. Following PRL stimulation, there was also significant increase in levels of pPRLr-Y381 and pPRLr-Y587 within 7.5–15 min, whereas a concomitant 2- to 5-fold decrease in phosphorylation with NIM811 treatment was observed as a function of time (Figure 1). Src is an associated kinase of the PRLr/Jak2 complex, and Src-Y416 residue is involved in Src activation. In Figure 1, a marked increase in Src phosphorylation occurred within 7.5–15 min of PRL stimulation with a concomitant >3-fold decrease in phosphorylation observed when treated with NIM811. Stat5 phosphorylation is mediated by the Jak2 tyrosine kinase at tyrosine residue 694 (Clevenger, 2004). Following PRL stimulation, Stat5 was significantly tyrosine phosphorylated within 7.5–30 min while demonstrating an associated 5- to 7-fold decrease in level of p-Y694 with NIM811 treatment as a function of time (Figure 1). Furthermore, NIM811 significantly inhibited PRL-induced phosphorylation of downstream Akt and MAPK (Figure S1). Taken together, these data indicate that CypA inhibition by NIM811 significantly decreases phosphorylation/activation of PRLr-Stat5 signaling intermediates that have been implicated in regulating downstream gene expression and breast cancer cell functions.

Loss of Function or Rescue of CypA Modulates Phosphorylation of PRLr-Stat5 Signaling Intermediates

A loss-of-function approach was used to identify the CypA-binding site at proline 334 on the PRLr (Zheng et al., 2008). Previously, when cells expressed the CypA interaction-defective mutant PRLr-P334A, a
**Figure A**

| Time (mins) | 0' | 0' | 7.5' | 7.5' | 15' | 15' | 30' | 30' |
|-------------|----|----|------|------|-----|-----|-----|-----|
| P-Jak2 Y1007/1008 | -  | +  | +    | -    | +   | +   | -   | +   |
| Jak2 | 150 KD |
| P-Stat5 Y694 | -  | +  | +    | +    | +   | +   | +   | +   |
| Stat5 | 75 KD |
| P-PRLr Y381 | -  | +  | +    | +    | +   | +   | +   | +   |
| P-PRLr Y587 | -  | +  | +    | +    | +   | +   | +   | +   |
| P-Src Y416 | -  | +  | +    | +    | +   | +   | +   | +   |
| Src | 50 KD |
| CypA | 20 KD |
| GAPDH | 37 KD |

**Figure B**

- **P-Jak2 Y1007/1008**
  - DMSO + PRL
  - PRL + NIM811

- **P-Stat5 Y694**
  - DMSO + PRL
  - PRL + NIM811

- **P-PRLr Y381**
  - DMSO + PRL
  - PRL + NIM811

- **P-PRLr Y587**
  - DMSO + PRL
  - PRL + NIM811

- **P-Src Y416**
  - DMSO + PRL
  - PRL + NIM811
significantly decreased CypA-PRLr association, Jak2/Stat5 phosphorylation, and PRL-induced gene expression were observed compared with CypA wild-type (WT) control (Zheng et al., 2008). Given the effects of NIM811 treatment on breast cancer cell signaling (Figures 1A and 1B) and PRLr mutant action on Jak2/Stat5 phosphorylation (Zheng et al., 2008), it was reasoned that such loss of function of CypA could alter phosphorylation/activations of PRLr-Stat5 signaling intermediates as well. To determine the consequences of molecular knockdown of CypA in breast cancer cell signaling, inducible short hairpin (shRNA)-mediated knockdown of CypA was performed in ER/PR+ T47D cells (Figure S2). Like the pharmacological inhibition of CypA PPI activity by NIM811, loss of its expression in breast cancer cells had significant effects on phosphorylation/activation of the PRLr, Jak2, Stat5, and Src in a PRL-dependent manner. Following PRL stimulation for 15 min, as expected, pYJak2 was significantly induced with prolactin stimulation in control cells, whereas >5-fold reduction in pYJak2 level was observed with the loss of CypA (Figures 2A and 2B). pPRLr-Y381 and pPRLr-Y587 were induced markedly in the shRNA control condition; however, in the CypA knockdown condition, a significant (>4-fold) decrease in phosphorylation was observed at these sites in T47D cells (Figures 2A and 2B). Last, Jak2-mediated phosphorylation of Stat5 was significantly induced by PRL stimulation, whereas a >7-fold reduction in phosphorylation was observed in the absence of CypA (Figures 2A and 2B). To determine if the loss of phosphorylation of PRLr-Stat5 intermediates was directly due to CypA knockdown and not an off-target effect, a rescue overexpression was performed. T47D cells with CypA knockdown were transfected with CypA-WT plasmid (Zheng et al., 2008), and subsequently cell lysates were analyzed. The rescue overexpression of CypA in the CypA knockdown cells was adequate to restore p-YPRLr, pYJak2, pYStat5, and pYSrc levels to PRL-induced endogenous levels (Figures 2C and 2D). Taken together, these data indicate that loss of CypA had significant effects on tyrosine phosphorylation of PRLr-Stat5 intermediates, which was rescued by WT CypA expression.

Furthermore, NIM811 treatments of CypA-WT cell decreased levels of p-Stat5, whereas CypA knockdown cells demonstrated no significant further reduction in p-Stat5 levels following the addition of NIM811 (Figure S3). This demonstrates that off-target actions of NIM811 are not the principal basis of its action on the PRLr-Stat5 axis.

CypA Inhibition Decreases mRNA and Protein Expression Levels of CISH and Cyclin D1

PRL and its cognate receptor regulate downstream genes through the Jak2-Stat5 signaling pathway. PRL signaling in breast cancer cells induces several breast cancer-relevant genes including the estrogen receptor (ER), cyclin D1, and CISH (Fang et al., 2009). These genes have been implicated in the pathogenesis of breast cancer (Raccurt et al., 2003; Sherr, 1996). To that end, the alteration of PRL-responsive gene expression by the NIM811-mediated inhibition of CypA was examined. mRNA and protein expression of CISH and cyclin D1 were assessed in NIM811 pre-treated ER/PR+ T47D breast cancer cells utilizing qRT-PCR and immunoblot analysis, respectively. As demonstrated in Figure 3A, CISH and cyclin D1 mRNA levels were significantly down-regulated with NIM811 treatment in a PRL-dependent manner. Furthermore, NIM811 treatment also resulted in a highly significant decrease in PRL-induced expression of both CISH and cyclin D1 at the protein level (Figure 3B) based on quantification of their normalized expression (Figures 3C and 3D). Overall, these findings demonstrated that inhibition of CypA prolyl isomerase activity directly correlated with PRL-induced gene expression of CISH and cyclin D1.

CypA Inhibition Alters Global Gene Expression in Breast Cancer Cells

In a precedent study, microarray analysis revealed 120 PRL-induced genes up-regulated by WT, but not mutant (mutation in the trans-activation domain) PRLr in T47D cells (Fiorillo et al., 2013). We reasoned that inhibition of the PPI activity of CypA may alter PRL-induced global gene expression based on its role in structure/function relationships of the PRLr and associated proximal/downstream signaling. To
determine the extent to which PRL and NIM811 altered global gene expression in human breast cancer cells, RNA derived from T47D cells treated with PRL and/or NIM811 was analyzed by expression microarrays. Analysis of the resultant data with a fold change cutoff of 1.2 revealed that PRL induced the expression of 535 genes and inhibited the expression of 372 genes, whereas NIM811 induced 1,725 genes and inhibited 1,737 genes. NIM811 inhibited expression of the PRLr target genes \textit{CCND1} and \textit{CEBPB} and opposed the expression changes stimulated by PRL on a global scale (Figure 4). NIM811 significantly inhibited 57% of the top 100 prolactin-induced genes (Figure 4A) and significantly induced 62% of the top 100 PRL-inhibited genes (Figure 4B). Of the 535 and 372 genes induced and inhibited, respectively, by PRL, NIM811 significantly inhibited 50% (268/535) and induced 50% (185/372). The global effects of NIM811 on PRL-induced Stat5 gene expression were also examined. Indeed, utilizing a previously reported set of Stat5 target genes (Kang et al., 2014b), we found that of the 46 Stat5 target genes significantly induced by PRL, 52% (24/46) were also significantly inhibited by NIM811 (Figure 4C). Of the 26 Stat5 target
genes significantly inhibited by PRL, 62% (16/26) were significantly induced by NIM811 (Figure 4D). Last, consistent with CypA's regulation of the PRLr with respect to Jak2 in the PRLr-Stat5 signaling cascade, gene set enrichment analysis comparing NIM811-inhibited genes with GEO (Gene Expression Omnibus) kinase perturbation experiments revealed highly significant similarity with Jak2 knockdown signatures (Figure 4E).

NIM811 Inhibits Breast Cancer Cell Viability, Anchorage-Independent Growth, Motility, and Migration

Breast cancer cell growth, particularly anchorage-independent growth, is a key hallmark of breast cancer development and progression (Paoli et al., 2013). Given that CypA function significantly impacts the PRLr and its associated signaling machinery that contributes to the pathogenesis of breast cancer (Ryczyn et al., 2000), it was reasoned that utilization of non-immunosuppressive PPI inhibitor such as NIM811 might inhibit the malignant phenotype of breast cancer. Thus the effects of NIM811 treatment on breast cancer proliferation, viability, and anchorage-independent growth in vitro were examined. Proliferation of ER/PR+(T47D) cells treated with NIM811 or CypA-knockdown was significantly inhibited in a PRL-dependent manner, as measured by CyQuant assay (Figure S4). When cultured in the presence of NIM811, both T47D and MDA231(ER/PR+/C0) cells demonstrated a dose-dependent inhibition of cell viability (Figure 5A). Furthermore, there were similar effects in inhibition of cell viability of BT-474 (HER-2 positive) and T47D cells compared with MDA-231 cells (data not shown). Furthermore, there was a marked and dose-dependent increase in cleaved-caspase 3 and cleaved-PARP as a function of this treatment, indicating dose-related induction of apoptosis by NIM811 (Figure S5). To determine the effects of NIM811 on anchorage-independent growth, soft-agar colony formation assays were performed. As demonstrated in Figure 5B, NIM811 treatment markedly reduced anchorage-independent growth of T47D and MDA 231.
breast cancer cells in a dose-dependent manner (Figure 5B). As a whole, these data indicate that as a non-immunosuppressive PPI inhibitor NIM811 can modulate in vitro malignant phenotypes of breast cancer cells in a dose-dependent manner.

Prolactin also stimulates the cytoskeletal re-organization and motility of breast cancer cells by activating Nek3 and Vav2 pathways (Miller et al., 2005). Given this, the motility and migration of T47D and MDA231 cells was assessed utilizing wound-healing and trans-well migration assays (Schmitt et al., 2016). As shown in Figure 6A, NIM811 significantly reduced the migration of both ER/PR+ and ER/PR− breast cancer cells (Figure 6B). These data demonstrated that NIM811 treatment significantly inhibits both the motility and migration of breast cancer cells.

CypA Inhibition Induces Tumor Necrosis and Inhibits Lymph Node Metastasis in TNBC Xenografts

To test the in vivo effects of CypA inhibition by NIM811, various in vivo settings were examined. MDA-231 breast cancer cells were injected into the fourth lactiferous ducts of nude mice (Harrell et al., 2006), and tumors were allowed to establish for 2 weeks or tumor size at 100–200 mm³. Subsequently a twice daily

Figure 4. NIM811 Opposes Prolactin-Induced Gene Expression Globally and at Stat5 Target Genes

(A and B) Heatmaps depict hierarchical clustering of the top 100 PRL-induced (A) and PRL-inhibited (B) genes (represented by rows) identified by microarray analysis. Samples are represented by columns and cluster with biological replicates according to the treatment conditions indicated above each dendrogram. Red and blue represent high and low gene expression values, respectively.

(C and D) Venn diagrams quantify the Stat5 target genes defined as those previously reported by Kang et al. (2014a), from the microarray analysis that are significantly induced (C) or inhibited (D) by PRL (fold change>1.2) and that are also significantly inhibited (C) or induced (D) by NIM811. Differential expression between treatment conditions was assessed by moderated t test adjusted for multiple hypotheses by the Benjamini and Hochberg method. The false discovery rate (FDR) was controlled so that only those probe sets with q < 0.01 were deemed significant.

(E) Bar graph depicts the highest scoring gene set enrichments when NIM811-inhibited genes (fold change>1.2) are compared with gene signatures from kinase perturbation experiments deposited in the Gene Expression Omnibus (GEO). The gene signatures with the highest concordance with NIM811-inhibited gene set are listed in descending order from top to bottom (# 1–8) based on p value ranking. (1) Jak2_knockdown_192_GSES4645, p < $3.18 \times 10^{-12}$; (2) LRRK2_activemutant_159_GSE36321, p < $3.50 \times 10^{-12}$; (3) LRRK2_mutant_GDS4401, p < $5.24 \times 10^{-12}$; (4) GSK3b_knockdown_206_GDS4305, p < $2.27 \times 10^{-5}$; (5) SYK_druginhibition_153_GSE34176, p < $5.22 \times 10^{-9}$; (6) SYK_druginhibition_154_GSE34176, p < $1.23 \times 10^{-9}$; (7) IGF1R_druginhibition_46_GSE14024, p < $1.62 \times 10^{-7}$; and (8) JAK1_druginhibition_166_GSE38333, p < $3.79 \times 10^{-7}$.
Gavage of NIM811 (or carrier control) was administered for 4 weeks. Although all NIM811-treated tumors revealed a trend toward a reduction in volume over the period, these parameters did not achieve statistical significance (Figure S6). However, two parameters were found to be markedly altered as functions of NIM811 treatment, namely, central tumor necrosis and lymph node metastasis. As demonstrated in Figure 7A, central necrosis of MDA-231 tumors treated with NIM811 was significantly increased compared with vehicle control. NIM811 effectively induced central tumor death at both 20 and 50 mg/kg/day doses based on quantification of necrotic area (Figure 7A). As shown in Figure 7B, NIM811 also markedly decreased lymph node metastasis of triple-negative breast cancer (TNBC) xenografts. Notably, 20 mg/kg/day dose of NIM811 was sufficient to significantly inhibit lymph node macro-metastasis (Figure 7B). Interestingly, although individual GFP-positive MDA-231 cells were observed in xenograft lymph nodes, the outgrowth of macro-metastasis was completely inhibited in these mice (Figure S7). Taken together, NIM811 therapy had significant effects on inhibition of the outgrowth of lymph node metastasis and extent of central tumor necrosis in TNBC xenografts.

**Loss of CypA Reduces Tumor Burden and Lung and Lymph Node Metastasis in an Oncogene-Driven Breast Cancer Model**

To demonstrate the loss of function of CypA (genetic knockout) in delaying or disrupting tumorigenesis and/or metastasis in a murine model with an intact immune system, the CypA-/- mouse was crossed into an MMTV-PyMT transgenic mammary mouse model (Ren et al., 2002; Sakamoto et al., 2010; Shen and...
Brown, 2005). This model demonstrates stochastic progression of tumorigenesis, with overlapping phases of hyperplasia, adenoma, invasion, and metastases. CypA+/− FVB/NJ and PyMT+/− FVB/NJ mice were mated. The resultant female PyMT+ CypA+/−/− progeny were followed for mammary tumor development and distal metastasis evaluated at 5–14 weeks of age. As presented in scatterplot in Figure S8A, a significant delay in tumor latency was noted in the PyMT+ CypA+/−/− mice (PyMT+ CypA+/+ mean latency = 36 days versus PyMT+ CypA−/− = 51 days). Analysis of mammary tumor multiplicity in the mouse cohorts at the time of euthanasia/death showed that PyMT+ CypA+/+ mice developed (average of 10 tumors/mouse) and demonstrated significantly more discrete carcinomatous foci than did PyMT+ CypA−/− mice (average of 5 tumors/mouse) (Figure S8B). In parallel, survival of the PyMT+ CypA+/− females was significantly enhanced (PyMT+ CypA+/+ = 129 days versus PyMT+ CypA−/− = 90 days) (Figure S8C). However, PyMT+ CypA+/− (heterozygous) females demonstrated no increase in tumor latency or survival, paralleling the curves of the PyMT+ CypA+/+ mice. To assess mammary cancer progression in this model, morphology was examined in both the PyMT+ CypA+/− and PyMT+ CypA+/+. In regard to the classic PyMT+ FBV/NJ, age correlated to a particular cancer stage: 5 weeks to hyperplasia, 8 weeks to adenoma, 11 weeks to invasive carcinoma, and 13 weeks to metastasis (Figure 8A). PyMT+ CypA+/+ and PyMT+ CypA+/− mice demonstrated significantly more invasive carcinoma at 11 weeks and metastasis at 13 weeks compared with PyMT+ CypA−/− mice (Figures 8A and S8D). The PyMT+ CypA−/− cohort had a preponderance of tumors with hyperplasia but significantly less-invasive carcinoma compared with either CypA+/+ or CypA+/− cohort at 13 weeks of age (Figure S8D). As the metastatic phenotype is related to primary tumor burden, tumorigenesis within the mammary glands of CypA+/+, CypA+/−, and CypA−/− mice was assessed. The primary tumor burden for CypA−/− mice was significantly decreased compared with CypA+/+ mice, whereas only moderate decrease was observed for CypA−/− mice (Figure 8B). In addition to primary...
tumorigenesis, metastases to both lymph nodes and lung metastasis was evaluated. Quantification of percent positive lymph nodes of CypA+/+, CypA+/−, and CypA−/− mice demonstrated that CypA−/− mice had a marked reduction in lymph node metastasis compared with CypA+/+ (Figure 8C). To determine lung metastasis, both the metastases area and the number of metastases were measured. CypA−/− mice demonstrated a significant decrease in both the number of metastases (Figure 8D) and metastases area (Figure 8E). Even after correction for primary tumor burden (Figure 8F), CypA−/− mice demonstrated reduced levels of metastases compared with CypA+/+ mice. These results demonstrated that loss of CypA and its corresponding function has profound impacts on the reduction of primary tumor burden and metastasis of lymph nodes and lung in mammary cancer, even after correcting for tumor burden. These data demonstrate that CypA significantly contributes to multistage mammary cancer progression.

DISCUSSION

The activation of the Jak2-Stat5 pathway is thought to play an important role in mammary tumorigenesis (Wagner and Rui, 2008). However, inhibitors of Jak2/Stat5 or the receptors associated with this complex’s activation have demonstrated limited success (Boussoik and Montazeri Aliabadi, 2018). In search for a better inhibitor of this pathway, our laboratory began to work with CypA, which through its prolyl isomerase activity is necessary for robust Jak2 activation. Use of CypA inhibitor, both in vitro and in vivo (Zheng et al., 2008), has significant effects on mammary tumorigenesis and progression. However, the immunosuppressive properties of CsA, through its engagement of calcineurin, preclude its use in patients with breast cancer with anything else other than end-stage disease. Thus, the development of non-immunosuppressive cyclosporines that remain fully functional as PPI inhibitors, such as NIM811, could have significant therapeutic impact. Herein, we demonstrate that NIM811 is fully capable at inhibiting the PRLr-triggered activation of the Jak2-Stat5 pathway and significantly alters breast cancer cell functions, mammary tumorigenesis, and metastasis.

The data presented here demonstrate that the PPI activity of CypA contributes to proximate PRLr receptor activation, enabling signal transduction through the PRLr/Jak2 complex. Inhibition of CypA PPI function by NIM811 blocked tyrosine phosphorylation of Jak2, Stat5, and Src at several sites that modulate the overall activity of these kinases. Similarly, NIM811 significantly reduced the phosphorylation of the PRLr itself, at residues 381 and 587, which are thought to play roles in the PRLr engagement of Src and Stat5, respectively (Brooks, 2012; Pezet et al., 1997). Like NIM811-mediated inhibition, CypA knockdown significantly suppressed phosphorylation of the PRLr, Jak2, and Src at those specific tyrosine residues (Figures 2A and 2B), confirming that CypA, and its prolyl isomerase activity, contributes to Jak2/Stat5 activity. Thus, the action of CypA may occur either through its direct inhibition of the Jak2 kinase or indirectly by inhibiting the larger interactions within the PRLr-Jak2 Complex.

NIM811 had significant effects on PRL-induced gene expression at both global and individual gene levels. Both CISH and cyclin D1 genes involved in the pathogenesis of breast cancer (Arnold and Papanikolaou,
Figure 8. Loss of CypA Reduces Tumor Burden and Lung and Lymph Node Metastases

(A) Representative images of H&E-stained mouse mammary gland containing tumor as a result of cross-breeding the WT (PyMT⁺) mouse to the Cyp A⁻⁄ mouse (n = 12). Different ages are representative of distinct cancer stages in the WT (PyMT⁺) model: 5 weeks, hyperplasia; 8 weeks, adenoma; 11 weeks, invasive carcinoma; 13 weeks, metastasis. Scale bar, 200 μm.

(B) Tumor burden was assessed as the sum of all primary mammary tumor volumes normalized to body weight in grams.

(C) Positivity of lymph nodes was determined as lymph nodes containing at least 1 macrometastasis from FFPE H&E-stained axillary and accessory axillary lymph nodes, assessed by C.V.C., a board-certified pathologist, under bright-field microscopy.

(D) Lung metastases from H&E-stained FFPE lung sections were counted.

(E) Borders were drawn of metastases identified in (D), and a scaled area was calculated for each metastasis as well as each lung lobe for each mouse. Total metastatic area was normalized to total lung area.

(F) Lung metastasis were counted and normalized per tumor burden. All experiments contained n = 12 mice per cohort. For (B and C), data reported as means with SEM. For primary tumor (B) and percent of total positive lymph nodes analysis (C), one-way ANOVA with Tukey’s tests for multiple comparisons were used to determine significance. For (D–F) medians with range were reported due to the lack of a normal distribution of the metastasis data. A non-parametric test for three groups was performed due to the lack of a normal distribution of the data. **p < 0.01, ***p < 0.005, ****p < 0.001.

2005; Borges et al., 2008) demonstrate significantly reduced expression at the RNA and protein levels (Figure 3). Transcriptomic analysis revealed the global contribution of CypA to PRLr-induced gene expression identifying several PRL-induced and NIM811-inhibited genes such as EGR3, KLF4, and LIN28A. Each of these genes has been found to contribute to the pathobiology of breast cancer, as follows: (1) ERG3 is a regulator of estrogen-mediated invasion and a potent prognostic factor in breast cancer (Suzuki et al., 2007); (2) KLF4 is required for maintenance of breast cancer stem cells, migration, and invasion (Yu et al., 2011); and (3) Lin28A facilitates breast cancer metastasis and promotes cell cycle by regulating cyclin D1 (Xiong et al., 2017). Functional analyses revealed that these data found cancer, cellular proliferation/growth, migration/invasion, and gene expression as the top molecular functions affected by NIM811 treatment. The fact that NIM811 down-regulated 57% of top 100 PRL-induced genes involved in a proliferative...
and migratory/invasive phenotype is strengthened by our observation that NIM811 also decreased the proliferation, anchorage-independent growth, and migration of breast cancer cells. Furthermore, when NIM811-inhibited genes were compared with gene signature from kinase perturbation experiments in the GEO database, significant similarities between Jak2 knockdown, LRRK2 (kinase) mutant, GSK3β knockdown, SYK and IGF1 inhibition, and NIM811-treated cohorts were observed. Not surprisingly, the Jak2 knockdown array generated the most similar gene signature as our CypA inhibition array, further confirming the relationship between these enzymes. It is interesting to note that leucine-rich repeat kinase 2 (LRRK2) mutant that induces progressive degeneration of human neural stem cells (Liu et al., 2012) is also associated with breast cancer (Waro and Aasly, 2018), but its mechanistic role is poorly understood. Glycogen synthase kinase 3β (GSK3β) interacts with the PRLr (Plotnikov et al., 2008) and is activated by the PRLr, hence the relation between it and the NIM811 gene set. Likewise, SYK kinase appears to be activated by the PRLr (Saha et al., 2009). Similarly, IGF signaling directly affects PRLr transduction and has a recognized role in breast cancer pathobiology (Carver et al., 2010). Taken together, these findings suggest that CypA is a key regulator of PRL-induced global genes that are implicated in inducing malignant phenotypes in breast cancer.

Treatment of murine xenograft model of TNBC breast cancer with NIM811 resulted in decreased lymph node metastasis and induction of necrosis, which are likely due to changes in receptor proximal signaling (Figures 1 and 2) and gene expression (Figures 3 and 4). Interestingly, whereas NIM811 therapy modestly affected tumor volume in vivo, treatment of TNBC xenografts with NIM811 induced central tumor cell death and the outgrowth of macro-metastasis. This phenomenon was also seen with the immunosuppressive, CsA (Zheng et al., 2008). There are a few of potential mechanisms through which these NIM811-mediated effects on xenograft progression may have been executed. The blockade of the PRLr-Jak2-Stat5 pathway, the activity of which has been linked to malignant phenotypes of human breast cancer (Holtkamp et al., 1984), is perhaps the most obvious. However, NIM811 treatment also significantly reduced PRL-responsive regulatory genes such as CISH and cyclinD1 as well as the global network of genes involved in promoting cancer malignancies (Figure 4).

The ability of NIM811 to block the malignant phenotype in vitro of breast cancer cells (Figures 5 and 6) revealed that NIM811 is equipotent to CsA at inhibiting proliferation, survival, motility, and anchorage-independent growth (Zheng et al., 2008). Similarly, NIM811 significantly inhibited lymph node and lung metastasis in vivo. As the sole functional difference between CsA and NIM811 is the ability of CsA to engage calcineurin (Ma et al., 2006), it is probable that the inhibition of calcineurin has little to do with the anti-cancer properties of the cyclosporine. Instead, these findings would argue that these properties reside in the ability of CsA and NIM811 to bind and block the prolyl isomerase activity of CypA, a finding further confirmed by the loss of signaling and anti-cancer of prolyl isomerase-defective form of CypA (Zheng et al., 2008).

This study used two complementary in vivo models of mammary carcinoma, namely, human xenografts and the PyMT mouse model. Each model has its advantages and disadvantages: whereas human xenograft models are performed in an immunocompromised model that lacks an immune system, the PyMT model is purely murine, but has an intact immune system. TNBC cells were introduced by teat injection (Harrell et al., 2006) into immunocompromised nude mice, and a significant reduction in lymph node metastasis (Figure 7B) and an increase in central tumor necrosis (Figure 7A) were observed. Although all NIM811-treated tumors revealed a trend toward a reduction in volume over the period, these parameters did not achieve statistical significance (Figure S6). Interestingly, although individual GFP-positive MDA231 cells were observed in xenograft lymph nodes, the outgrowth of macro-metastasis was completely inhibited in these mice (Figure S7). This would argue that NIM811 affects metastatic outgrowth, but does not alter micro-metastatic seeding, and further studies are planned to examine the mechanistic basis for this effect. Significant alterations in mammary cancer progression were also observed in the PyMT spontaneous model (Volker et al., 2018). CypA−/− × PyMT mice demonstrated a highly significant decrease in tumor burden in comparison with the CypA+/+ × PyMT cohorts (Figure 7). Loss of CypA in the PyMT mice demonstrated a significant difference in lymph node metastases compared with the WT control, even after correcting for tumor burden. Although the CypA−/− and Jak2−/− mice show parallels in their effects on tumor initiation (Sakamoto et al., 2009, 2010; Zheng et al., 2008), CypA−/− mice demonstrated a significant inhibition of metastasis, which was not observed in the Jak2−/− mice. This may be due to the additional signaling pathways inhibited by CypA, such as Src, Akt, and MAPK (Figure S1) (Garcia-Martinez et al., 2010; Watkins et al., 2008) (Zheng et al., 2008).
We have found that non-immunosuppressive NIM811 has profound effects on tumorigenesis, metastasis, and associated signaling in breast cancer cell and mammary cancer models. As a therapeutic agent, NIM811 and other non-immunosuppressive cyclosporines, such as Debio025 (alisporivir) SCY-635 and CRV431 have minimal toxicity and have successfully undergone phase I–III clinical trials for safety in patients (Lawitz et al., 2011; Sweeney et al., 2014). Additional pre-clinical studies with approved and experimental breast cancer therapeutics are warranted to identify additional synergies of these agents, given that their benign toxicity profile also hold promises as chemo-preventative agents.

Limitations of the Study
Investigation of mechanisms behind CypA regulation of the structure/functions relationships of the prolactin receptor would strengthen the conclusions of the study, which was beyond the scope of this article. Furthermore, NIM811 treatment of a PDX model would further demonstrate the efficacy of the drug in a relevant breast cancer model in addition to the mammary xenografts study included in this article.

Resources Availability
Lead Contact
Further information and requests should be directed to the Lead Contact, Charles V. Clevenger (Charles.clevenger@vcuhealth.org).

Materials Availability
Any unique reagents are available from the Lead Contact on request.

Data and Code Availability
The datasets supporting the current study are available from the corresponding author on request. The accession number for the microarray data reported in this paper is NCBI GEO: GSE151635.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101581.

ACKNOWLEDGMENTS
We thank Xianke Zeng for help with mouse xenograft studies and helpful discussions. We thank Senthil Radhakrishnan for critical review of this paper. Services and products in support of research project were generated by the Virginia Commonwealth Transgenic/knockout Mouse Core, Cancer Mouse Models Core Laboratory, and the VCU Microscopy Facility, supported in part with funding to the Massey Cancer Center from NIH-NCI Cancer Center Support Grant P30 CA016059 and by the Department of Pathology, Anatomic Pathology Research Services, at VCU Health. We thank Novartis for gifting NIM811. This work was supported in part by grants from the NIH, R01 CA173305.

AUTHOR CONTRIBUTIONS
S.H. performed all the experiments; S.H., J.M.C., and J.E.K., performed all analysis, and all authors wrote and edited the paper.

DECLARATION OF INTERESTS
No potential conflicts of interest were disclosed by the authors.

Received: March 27, 2020
Revised: April 27, 2020
Accepted: September 15, 2020
Published: October 23, 2020
REFERENCES

Arnold, A., and Pappaniolou, A. (2005). Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23, 4215–4224.

Borges, S., Mouadlou, E., Vouyouvitch, C., Chessa, J., Lobie, P., Mertani, H., and Raccurt, M. (2008). Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer. Adv. Exp. Med. Biol. 617, 321–329.

Bousoik, E., and Montazeri Alibadi, H. (2018). “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Front. Oncol. 8, 287.

Brockman, J.L., and Schuler, L.A. (2005). Prolactin receptors. J. Biol. Chem. 280, 8003–8012.

Broglio, C.V. (2004). Roles and regulation of statt family transcription factors in human breast cancer. Am. J. Pathol. 165, 1449–1460.

Clevegner, C.V. (2001). Prolactin receptor signal transduction. Lupus 10, 706–718.

DaSilva, L., Howard, O.M., Rui, H., Kirken, R.A., and Farrar, W.L. (1994). Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J. Biol. Chem. 269, 18267–18270.

Fang, F., Ryczyzyn, M.A., and Clevegner, C.V. (2009). Role of c-Myb during prolactin-induced signal transduction and activator of transcription 5a signal transduction in breast cancer cells. Endocrinology 150, 1597–1606.

Fiorillo, A.A., Medley, T.R., Feeney, Y.B., Wetz, S.M., Tommerdahl, K.L., and Clevegner, C.V. (2013). The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer. Am. J. Pathol. 182, 217–233.

Gadd, S.L., and Clevegner, C.V. (2006). Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20, 2734–2746.

Garcia-Martinez, J.M., Calcabrini, A., Gonzalez, L., Martin-Forero, E., Aguilo-Ottuno, M.T., Simon, V., Watkin, H., Anderson, S.M., Roche, S., and Martin-Perez, J. (2010). A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal 22, 415–426.

Gertler, A., Grosclaude, J., Strasburger, C.J., Nir, S., and Djiane, J. (1996). Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. J. Biol. Chem. 271, 24482–24491.

Goethel, S.F., and Marahiel, M.A. (1999). Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell. Mol. Life Sci. 55, 423–436.

Handschumacher, R.E., Harding, M.W., Rice, J., Drugg, R.J., and Speicher, D.W. (1994). Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226, 544–547.

Harrell, J.C., Dye, W.W., Allred, D.C., Jedlicka, P., Spoelstra, N.S., Sartorius, C.A., and Horwitz, K.B. (2006). Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 66, 9308–9315.

Hollkamp, W., Nagel, G., Wander, H., Rauschecker, H.F., and von Heyden, D. (1986). Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J. Cancer 34, 323–328.

Kang, K., Yamaji, D., Yoo, K.H., Robinson, G.W., and Hennighausen, L. (2014a). Mammary-specific gene activation is defined by progressive recruitment of STAT5 during pregnancy and the establishment of H3K4me3 marks. Mol. Cell Biol. 34, 464–473.

Kang, K., Yamaji, D., Yoo, K.H., Robinson, G.W., and Hennighausen, L. (2014b). Mammary-specific gene activation is defined by progressive recruitment of STAT5 during pregnancy and the establishment of H3K4me3 marks. Mol. Cell Biol. 34, 464–473.

Kelly, P.A., Binart, N., Freeman, M., Lucas, B., Goffin, V., and Bouchard, B. (2001). Prolactin receptor signal transduction pathways and actions determined in prolactin receptor knockout mice. Biochem. Soc. Trans. 29, 48–52.

Lammers, M., Neumann, H., Chin, J.W., and Hennighausen, L. (2014b). Mammary-specific gene activation is defined by progressive recruitment of STAT5 during pregnancy and the establishment of H3K4me3 marks. Mol. Cell Biol. 34, 464–473.

Lawitz, E., Godofsky, E., Rouzier, R., Marbury, T., McGuckin, M.A., Morel, G., et al. (2003). Progressive degeneration of human immunodeficiency virus infected patients receiving 14 days of therapy. Antivir. Res. 50, 544–547.

Lambert, A., Garcia-Caballero, T., Li, H., Brown, P.J., Rui, H., and Fuchs, S.Y. (2008). Oncogene-suppressor of cytokine signalling gene 3 beta impair degeneration of prolactin receptor. Cancer Res. 68, 1354–1361.

Lobie, P., Mertani, H., and Raccurt, M. (2008). JAK/STAT signaling pathway. Front. Oncol. 19, 939–949.

Marti, H.C., Garcia-Caballero, T., Lambert, A., Gerard, F., Palayer, C., Boutin, J.M., Vanderhaar, B.K., Waters, M.J., Lobie, P.E., and Morel, G. (1998). Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer 79, 202–211.

Miller, S.L., DeMaria, J.E., Freier, D.O., Riegel, A.M., and Clevegner, C.V. (2005). Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol. Endocrinol. 9, 39–49.

Montazeri Aliabadi, H., Montazeri Aliabadi, K., and Chiraghi, P. (2013). Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acts 1833, 3481–3498.

Perks, C.M., Keith, A.J., Goodhew, K.L., Savage, J., Winters, Z.E., and Holly, J.M. (2004). Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer 91, 305–311.

Pezet, A., Ferrag, F., Kelly, P.A., and Edery, M. (1997). Tyrosine docking sites of the rat prolactin receptor required for association and activation of Stat5. J. Biol. Chem. 272, 25043–25050.

Pietnikow, A., Li, Y., Tran, T.H., Tang, W., Palazzo, J.P., Rui, H., and Fuchs, S.Y. (2008). Oncogene-mediated inhibition of glycosyn synthase kinase 3 beta impairs degeneration of prolactin receptor. Cancer Res. 68, 1354–1361.

Raccurt, M., Tam, S.P., Lau, P., Mertani, H.C., Lambert, A., Garcia-Caballero, T., Li, H., Brown, R.J., McGuckin, M.A., Morel, G., et al. (2003). Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br. J. Cancer 89, 524–532.

Ren, S., Cai, H.R., Li, M., and Furt, P.A. (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21, 4335–4339.

Roehl, M.H., Kang, S., Aramburu, J., Wagner, G., Rao, A., and Hogan, P.G. (2004). Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc. Natl. Acad. Sci. U S A 101, 7594–7599.

Ryczyzyn, M.A., Reilly, S.C., O’Malley, K., and Clevegner, C.V. (2000). Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol. Endocrinol. 14, 1175–1186.

Saha, S., Gonzalez, J., Rosenfeld, G., Keiser, H., and Peeva, E. (2009). Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 60, 1743–1752.

Sakamoto, K., Lin, W.C., Triplett, A.A., and Wagner, K.U. (2009). Targeting janus kinase 2 in
Her2/neu-expressing mammary cancer: implications for cancer prevention and therapy. Cancer Res. 69, 6642–6650.

Sakamoto, K., Triplett, A.A., Schuler, L.A., and Wagner, K.U. (2010). Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene 29, 5359–5369.

Schindler, C., Shuai, K., Prezioso, V.R., and Darnell, J.E., Jr. (1992). Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809–813.

Schmitt, D., Andrews, J., and Tan, M. (2016). Determination of breast cancer cell migratory ability. Methods Mol. Biol. 1406, 171–180.

Shen, Q., and Brown, P.H. (2005). Transgenic mouse models for the prevention of breast cancer. Mutat. Res. 576, 93–110.

Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672–1677.

Stewart, T., Tsai, S.C., Grayson, H., Henderson, R., and Opelz, G. (1995). Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346, 796–798.

Suzuki, T., Inoue, A., Miki, Y., Manyo, T., Akahira, J., Ishida, T., Hirakawa, H., Yamaguchi, Y., Hayashi, S., and Sasano, H. (2007). Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic factor. Endocr. Relat. Cancer 14, 279–292.

Sweeney, Z.K., Fu, J., and Wiedmann, B. (2014). From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. J. Med. Chem. 57, 7145–7159.

Syed, F., Ryczyn, M.A., Westgate, L., and Clevenger, C.V. (2003). A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine 20, 83–90.

Volker, S.E., Hedrick, S.E., Feeney, Y.B., and Clevenger, C.V. (2018). Cyclophilin A function in mammary epithelium impacts jak2/stat5 signaling, morphogenesis, differentiation, and tumorigenesis in the mammary gland. Cancer Res. 78, 3877–3887.

Wagner, K.U., Kremppler, A., Triplett, A.A., Qi, Y., George, N.M., Zhu, J., and Rui, H. (2004). Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell Biol. 24, 5510–5520.

Wagner, K.U., and Rui, H. (2008). Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 13, 92–103.

Wang, P., and Heitman, J. (2005). The cyclophilins. Genome Biol. 6, 226.

Waro, B.J., and Aasly, J.O. (2018). Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson’s disease. Brain Behav. 8, e00858.

Watkin, H., Richert, M.M., Lewis, A., Terrell, K., McManaman, J.P., and Anderson, S.M. (2008). Lactation failure in Src knockout mice is due to impaired secretory activation. BMC Dev. Biol. 8, 6.

Xiong, H., Zhao, W., Wang, J., Seifer, B.J., Ye, C., Chen, Y., Jia, Y., Chen, C., Shen, J., Wang, L., et al. (2017). Oncogenic mechanisms of Lin28 in breast cancer: new functions and therapeutic opportunities. Oncotarget 8, 25721–25735.

Yu, F., Li, J., Chen, H., Fu, J., Ray, S., Huang, S., Zheng, H., and Ai, W. (2011). Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30, 2161–2172.

Zheng, J., Koblinski, J.E., Dutson, L.V., Feeney, Y.B., and Clevenger, C.V. (2008). Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res. 68, 7769–7778.
Supplemental Information

Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases

Shawn Hakim, Justin M. Craig, Jennifer E. Koblinski, and Charles V. Clevenger
**Figure S1. NIM811 inhibits phosphorylation of AKT and MAPK, related to Figure 1.**

(A) T47D Cells were serum starved for 16-24 hours, pre-treated with NIM811 (10 µg/ml) for 4-6 hours and/or stimulated with PRL (250 ng/ml) at the indicated times. Blots were probed with the indicated antibodies. (B, C) Quantification of fold expression of phosphoproteins (pAKT and pMAPK) normalized to their respective total proteins in panel A as indicated. Quantification of blots in panel A. *Column, mean of three independent experiments; error bars, ±SEM. *P < 0.05, ***P < 0.005. T-test was performed to determine significance.
Figure S2. Both shRNA sequences targeting CypA demonstrate effective knockdown of the protein and phosphorylation of signaling intermediates, related to Figure 2. Stable expression of non-silencing control or CypA shRNA in T47D were serum starved for 16-24 hours, stimulated with PRL (250 ng/ml) for 15 minutes and blots were probed with the indicated antibodies.
Figure S3. NIM811 inhibits phosphorylation of Stat5 only in CypA-expressing cells, related to Figure 2. (A) Stable expression of non-silencing control shRNA in T47D were serum starved for 16-24 hours, pre-treated with NIM811 for 4 hours and stimulated with PRL (250 ng/ml) for 15 minutes and blots were probed with the indicated antibodies. (B) Stable expression of CypA shRNA were treated as indicated above and blots were probed with indicated antibodies.
Figure S4. Inhibition or knockdown of CypA significantly decreases breast cancer cell proliferation, related to Figure 5. (A & B) Cell proliferation was measured by CyQuant (Thermo Fisher) proliferation assay. (A) Cells were pre-treated with NIM811 (10 µg/ml) and/or PRL (250 ng/ml). (B) Non-targeting control or CypA shRNA transfected in T47D cells and/or PRL (250 ng/ml). Columns, mean of three independent experiments; error bars, ±SEM. **P < 0.01, ***P < 0.005. One-way ANOVA with Tukey’s test was used to determine significance.
Figure S5. Treatment of high dose of NIM811 induces apoptosis, related to Figure 5. T47D cells were treated with various doses of NIM811 for 96 hours. Cell lysates were collected and immunoblotted with PARP or cleaved caspase 3 antibody as indicated. α-Tubulin is used as the loading control.
Figure S6. NIM811 treatment does not alter tumor growth, related to Figure 7. Quantification of primary tumor volume based on caliper measurements on the indicated days for each cohort. The difference in tumor volume between control vs. treatment(s) is not significant, $P < 0.149$. One-way ANOVA was used to determine significance.
Figure S7. NIM811 therapy prevents macrometastastic outgrowth in GFP-labeled MDA231 xenografts, related to Figure 7. IF analyses for GFP label present in the xenografts treated 6 weeks with 50 mg/kg/day NIM811 (or carrier control; treatment initiated after 2 weeks of outgrowth) is presented in the upper panels, bar “_” = 1 cm; IHC confirmation with a-human HLA1 antibody is seen in lower panels, bar “_” = 100 µm.
Figure S8. CypA deletion markedly inhibits PyMT mammary tumorigenesis, related to Figure 8. (A) CypA\(^{-/-}\) x PyMT\(^{+}\) mice demonstrate significantly delayed tumor latency (***\(P < 0.005\)). One-way ANOVA with Dunnett’s test was used to determine significance. (B) Compared to CypA\(^{+/+}\) x PyMT\(^{+}\), CypA\(^{-/-}\) x PyMT\(^{+}\) mice demonstrate significantly reduced number of primary tumors (***\(P < 0.005\)). One-way ANOVA with Dunnett’s test was used to determine significance. (C) Kaplan-Meier plots of overall survival (\(P < 0.0006\)) reveal highly significant differences between Cyp A\(^{+/+}\) and Cyp A\(^{-/-}\) mice when
bred into the PyMT mouse model of mammary tumorigenesis. (D) Percent cancer phenotypes based on histological analysis under brightfield microscopy. Percent of total denotes the portion of FFPE mouse mammary gland H&E stained tissue sections exhibiting features of (1) invasive carcinoma, (2) adenoma, (3) hyperplasia, (4) normal mammary tissue. Statistics based upon an n = 12 for each cohort based upon comparison to WT (PyMT+) (***,p < 0.001). Two-way ANOVA with Dunnett’s test for multiple comparisons and based upon comparison to WT(PyMT) was used to determine significance.
Transparent Methods

Cell culture and reagent

T47D and MDA 231 human breast cancer cell lines were obtained from ATCC (Manassas, VA) and cultured in Dulbecco’s modified Eagles’s medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Life Technologies). All cells were incubated in a humidified 5% CO₂/95% air atmosphere at 37°C. Human recombinant PRL was a gift from Dr. Anthony Kossiakoff (University of Chicago, Chicago, IL). PRL was added to cells to yield a final concentration of 250 ng/ml. N-methyl-4-isoleucine-cyclosporin (NIM811) was obtained from Novartis and pre-incubated for 2-4 hours prior to stimulation with PRL.

shRNA Constructs

TripZ shRNA with mature antisense 5’-TAGGATGAAGTTCTCATCT-3’ (V3THS_304403) and 5’-TCTGCTGTCTTTGGGACCT-3’ (V3THS_304404) target sequences against PPIA (CypA) as well as non-targeting control shRNA controls were purchased from Dharmacon as glycerol stocks. Bacterial cultures were grown with Carbenicillin (100 μg/ml, Fisher Scientific) and subsequently plasmids were purified using EndoFreeR Plasmid Maxi Kit (Qiagen) according to the manufacturer’s instructions. Purified plasmid DNA were transfected in HEK 293T using Lipofectamine 3000 (Life Technologies) according to the manufacturer’s instructions.

Antibodies

Antibodies utilized for western blot analysis were obtained from the following sources and used as described: anti-pPRLr 381 (Custom antibody from New England Biolabs, 1:500), anti-pPRLr 587 (Custom antibody from New England Biolabs, 1:500), anti-PRLr (Life Technologies, 1:1000), anti-p-Jak2 1007/1008 (Cell Signaling Technology, 1:500), anti-Jak2 (Cell Signaling Technology, 1:1000), anti-pStat5 (Cell Signaling Technology, 1:1000), anti-Stat5 (Santa Cruz Biotechnology,
1:1500), anti-pSrc416 (Cell Signaling Technology, 1:500), anti-Src (Cell Signaling Technology, 1:1000), anti-CISH (Santa Cruz Biotechnology, 1:1000), anti-CyclinD1 (Santa Cruz Biotechnology, 1:1000), anti-Cyclophilin A (Santa Cruz Biotechnology, 1:1000), anti-GAPDH (Cell Signaling Technology, 1:2000), and anti-Tubulin (ABCAM, 1:1000) diluted in TBS-T with 3% milk or BSA as suggested by the specific manufacturer.

**Experimental Methods**

**Mouse MMTV-PyMT model**

For tumorigenesis studies, the well-recognized mouse model of transgene-driven tumorigenesis (Muller et al., 1988) utilizing the MMTV-driven expression of polyomavirus middle T in mouse mammary grands was employed. PyMT mice were purchased from The Jackson Laboratory (Jax; Stock # 002374, FVB/N-Tg(MMTV-PyVT)634Mul/J). Hemizygous males were cross-bred with our transgenic CypA−/+ female mice (Volker et al., 2018) until a PyMT+/CypA+/− male mouse was obtained. This sire was then bred with the Cyp A−/+ dams until PyMT+/CypA+/− and PyMT+/CypA−/− females were obtained for use in this study. Tumors were monitored beginning at weaning until time of dissection via palpating and calipering. Mice were kept in accordance to an approved IACUC protocol which allowed the humane endpoint of when any single tumor reached 17 mm in diameter. Dissection timepoints included 5 weeks (hyperplasia phase in PyMT model), 8 weeks (adenoma phase), 11 weeks (invasive carcinoma phase), and 13 weeks (distal metastasis phase). Mice were weighed and whole mammary glands containing tumors were calipered upon dissection. Lungs and lymph nodes were weighed and collected as well. Following fixation with 10% buffered neutral-buffered formalin, tumors were paraffin-embedded and processed for histologic and histochemical analyses.
Mouse xenograft model

Four to six weeks old female nude mice were used for the xenograft study. To assess the effects of NIM811 on the xenograft growth, MDA231 cells (0.5× 10^6) expressing mCherry fluorescent protein (Puchalapalli et al., 2016) were suspended in Matrigel and injected into the teat of the fourth abdominal mammary gland of nude mice as described (Harrell et al., 2006). When tumor volume reached 80-100 mm³, animals were randomized into three groups and were treated with vehicle control (olive oil) and NIM811 (20 mg/kg/day, 50 mg/kg/day) for 4 weeks by twice-daily gavages. Tumor growth was measured by weekly caliper measurement using the formula length × breadth²/2. In the end of experiment, mice were sacrificed. The entire primary mammary tumors were removed and weighed. In addition, all visceral organs, bones, brain, and superficial lymph nodes were harvested for microscopic examination for metastasis. Metastases were detected by the presence of mCherry fluorescent protein using Zeiss SteroDiscovery. V12 fluorescence dissecting microscope with an AxioCam MRm digital camera. One half of each tumor and other organs were fixed, embedded, sectioned, and stained with H&E. The necrotic area of primary tumor was quantified by morphometric determination of the proportion of total tumor area that was necrotic in H&E staining section.

Method Details

Western blotting and analysis

Cell lysates were analyzed by western blot analysis as previously described in (Zheng et al., 2008). Cells were grown in 100 cm² dishes until 70%-80% confluence followed by starvation for 16-24 hrs before PRL treatment (100 ng/ml) in conditioned media (DMEM, Life Technologies). Cells were lysed in RIPA buffer and cell lysates were blotted by specific antibodies as listed in the key resources section. Target proteins were visualized by enhanced chemiluminescence (GE
Healthcare), and images were captured using Fujifilm LAS-3000 system. The band intensities were quantified by LAS-3000 analysis tools and normalized to those of their respective loading control bands. Data were expressed as fold changes compared with an appropriate control.

**Lentivirus production and transduction**

Transfection of TripZ shRNA or control shRNA was performed with necessary components to produce/collection virus 48 hours post-transfection according to Dharmacon protocol/kit. T47D cells were infected with filtered virus and puromycin selected 48 hours post infection according to Dharmacon instructions. Following antibiotic selection, Doxycycline at a concentration of 1 µg/ml was used for induction of TurboRFP/shRNA expression.

**Cell viability**

Trypan blue exclusion method as described (Strober, 2001) was used to assess cell viability. 1 × 10^5 cells were plated and cultured for 24 hours, and then serum starved for overnight. Cells were treated with PRL and/or NIM811 in indicated concentrations for the indicated timepoints. DMEM, along with trypsinized cells were centrifuged at 200 x g, and then resuspended in PBS and Trypan blue. Cells were counted on a Countess Automated Cell Counter (Invitrogen) and percentage of live cells was calculated. Cell viability was measured in the same manner for duration of the experiment.

**Wound healing assay**

MDA231 and T47D confluent cell monolayers was wounded with a p200 pipette tip and cultured in serum-free medium in the presence of various concentrations of NIM811. Representative images of a wound closure assay were acquired with a phase-contrast microscope at indicated times. The wound areas were measured using Image J and the percentage of the wound closed was calculated.
**Boyden chamber migration assay**

MDA231 and T47D cells were placed in the top of a trans-well chamber with 8 µm pore polyethylene terephthalate (PET) membranes in the presence of various doses of NIM811. Serum free media (SFM) with 2% FBS medium were placed in the bottom of the chamber. After 24 hours, the number of cells migrating to the lower surface of the membrane was quantified by CyQuant™ (Invitrogen).

**Soft agar colony formation assay**

A bottom agar was prepared by solidifying 1 mL of 0.8% SeaPlaque agarose (BioWhitaker) in 10% FBS-containing growth media in each well of a 6-well plate. The bottom agar was overlaid with 800 µl of a 0.45% top agar mixture containing 10,000 cells per well in the presence of various concentration of NIM811. The plates were incubated at 37°C for 14 (MDA231 cells) to 21 (T47D cells) days, colonies were counted using a light microscope with an ocular grid. Only colonies (≥50 µm) were counted with Image J software. Five random fields were counted for each well and the average number of colonies per well is shown.

**RNA extraction, cDNA synthesis, and qRT-PCR**

T47D cells were plated in 10 cm plate as described in the later section and treated with DMSO (0.1%) control, PRL (250 ng/mL in 0.1% DMSO), and/or NIM811 (10 ug/ml in 0.1% DMSO). After treatments, cells were washed with PBS and mRNA was isolated with a PureLink™ RNA Mini Kit (Invitrogen/Fisher Scientific) according to manufacturer’s instructions. cDNA was synthesized using 1 µg of total mRNA with iScript™ Reverse Transcription Supermix (BioRad) according to the manufacturer’s protocol. qPCR was performed using iTaq™ Universal SYBR® Green Supermix (Biorad), 20 ng of DNA, and 1 nmol/L primers as follows: CCND1 forward 5’-CCGTCCATGCGGAAGATC-3’, reverse 5’-GAAGACCTCCTCCTCGACCTT-3’; CISH
forward  5’- AGAGGGATCTGCTGTGCAT-3’, reverse  5’-
GGAACCCCAATACCAGCCAG; GAPDH forward 5’- CATGAGAAGTATGACACAGCCT-
3’, Reverse 5’- AGTCCTTCCACGATACCAAAGT-3’ using a BioRad CFX96 Real-Time PCR
thermocycler. Data were normalized to GAPDH and fold change were represented as
$2^{-\Delta\Delta Ct} (2^{(Ct_{Target} \text{-} Ct_{GAPDH})_{PRL} - (Ct_{Target} \text{-} Ct_{GAPDH})_{Control}})$ using untreated DMSO control as baseline.

**Cell culture and RNA Isolation for microarray**

Differential gene expression was assessed in T47D cells treated with DMSO (0.1%) control, PRL
(250 ng/mL in 0.1% DMSO), and/or NIM811 (10 ug/ml in 0.1% DMSO). Prior to RNA isolation, T47D
cells were plated at 60% confluency in 10-cm plates and incubated for 24 hours in complete
media followed by an additional 24 hours of serum starvation in DMEM (Life Technologies) and
1X ITS Liquid Media Supplement (Sigma Aldrich). Cells were then treated for 4 hours with either
DMSO or NIM811 before stimulation with PRL. After 2-hour PRL stimulation, cells were washed
with PBS and RNA was extracted using the MagMAX-96 for Microarrays Total RNA Isolation
Kit (Invitrogen, Life Technologies) in an automated fashion using the magnetic particle processors
MagMAX Express. RNA purity was judged by spectrophotometry at 260, 270, and 280 nm. RNA
integrity was assessed by running 1 µl of every sample in RNA 6000 Nano LabChips on the 2100
Bioanalyzer (Agilent Technologies).

**Microarray hybridization and Data Acquisition**

Each of the four cell treatment conditions (PRL−/DMSO, PRL+/DMSO, PRL−/NIM811, 
PRL+/NIM811) were assessed in three independently grown biological replicates. Each of the 12
RNA samples were hybridized in duplicate to two Human Genome U133A 2.0 Arrays
(Affymetrix, Santa Barbara, CA) according to the Affymetrix protocol as previously described
(Dumur et al., 2004) with modifications: Starting with 500 ng of total RNA, we performed a
single-strand cDNA synthesis primed with a T7-(dT24) oligonucleotide. Second strand cDNA synthesis was performed with *E. coli* DNA Polymerase I, and biotinylation of the cRNA was achieved by in vitro transcription (IVT) reaction using the GeneChip 3’ IVT Express Kit (Affymetrix, Santa Clara, CA). After a 37°C-incubation for 16 hours, the labeled cRNA was purified using the cRNA cleanup reagents from the GeneChip Sample Cleanup Module. As per the Affymetrix protocol, 10 μg of fragmented cRNA were hybridized on the GeneChip HG U133A 2.0 Arrays (Affymetrix Inc., Santa Clara, CA) for 16 hours at 60 rpm in a 45 °C hybridization oven. The arrays were washed and stained using the GeneChip Hybridization, Wash, and Stain Kit in the Affymetrix fluidics workstation. Every chip was scanned at a high resolution, on the Affymetrix GeneChip Scanner 3000 7G according to the GeneChip Expression Analysis Technical Manual procedures (Affymetrix, Santa Barbara, CA). After scanning, the raw intensities for every probe were stored in electronic files (in .DAT and .CEL formats) by the GeneChip Operating Software v1.4 (GCOS) (Affymetrix, Santa Barbara, CA).

**Histology**

All mammary glands, lymph nodes, and lungs were fixed in 10% neutral buffered formalin (NBF) for 24-48 hours, depending on the size of the tumor, and then stored in 70% ethanol at 4 degrees. All tissues were processed together to form FFPE blocks and sectioned into 5 μm thick sections by the VCU Cancer Mouse Models Core laboratory as well as Anatomic Pathology Research Services at VCU Health for histological analysis by hematoxylin, gill no. 3 (cat. # GHS332, Sigma Aldrich, St. Louis, MO) and eosin Y (cat. # 318906, Sigma Aldrich, St. Louis, MO) staining as described (Volker et al., 2018). Positivity of lymph nodes was determined as lymph nodes containing at least 1 macro-metastasis. FFPE hematoxylin and eosin stained axillary and accessory axillary lymph nodes were assessed for presence of metastases by Dr. C.V. Clevenger, a board-
certified pathologist, under brightfield microscopy. Slides were then imaged with the NanoZoomer RS Digital Slide Scanner (Hamamatsu Photonics, Bridgewater, NJ) and analyzed using utilizing NDPview2 software (Hamamatsu Photonics). Lung metastases were counted, and borders of metastases drawn as free ROIs in this software. The software calculated a scaled area from the scanned image metadata. Areas of each metastasis as well as each lung lobe were totaled for each mouse. The metastasis area was normalized to total lung area and expressed as a percent to account for the anatomical size difference of the organs between the WT and KO mice (Volker et al., 2018).

**Quantification and Statistical Analysis**

**Differential Expression Analysis**

The 12 resultant .CEL files were analyzed using the R statistical computing language and environment (RDevelopmentCoreTeam, 2011). The data quality of each microarray was assessed by examining the average background, percent of probe sets called present by the MAS5 detection call algorithm (Gautier et al., 2004), and the 3′:5′ ratio for GAPDH and ACTIN. Additionally, to detect potential spatial artifacts resulting from sub-optimal hybridization conditions, probe level linear models were fit using the R Bioconductor package, “affyPLM”, and plots of the residuals were examined for each microarray (Bolstad et al., 2004; Gentleman et al., 2004). Differential expression was assessed using the “affy” and “limma” Bioconductor packages (Gautier et al., 2004; Smyth, 2004). Briefly, probesets were quantile normalized and processed by the Robust Multi-Array Average (RMA) algorithm (Irizarry et al., 2003) before the manufacturer’s control probesets and probesets considered “absent” in 20 or more arrays by the MAS5 algorithm were filtered from all arrays (Archer and Reese, 2010). Differential expression between treatment conditions was then assessed via moderated t-test adjusted for multiple hypotheses by the
Benjamini & Hochberg method (Benjamini and Hochberg, 1995). The false discovery rate (FDR) was controlled so that only those probesets with \( q < 0.01 \) were deemed significant.

Hierarchical clustering was performed on the top 100 prolactin induced and top 100 prolactin inhibited genes (as defined by the expression fold change between the PRL\(^+\) / DMSO and PRL\(^-\) / DMSO microarrays) utilizing the GenePattern public server (de Hoon et al., 2004; Eisen et al., 1998; Reich et al., 2006). Microarrays were clustered using a pairwise average-linkage method and Pearson correlation as the similarity metric; genes were not subjected to clustering and are presented as originally ordered in the .GCT file supplied to the module.

STAT5 target genes were defined as previously reported (Kang et al., 2014) and include genes flanked by the classic STAT5 palindromic repeat binding motif as well as those identified by Kang et al. utilizing STAT5 ChIP-seq on murine mammary tissues at parturition. After converting \textit{Mus musculus} gene annotations to human gene symbols, 847 unique genes comprised the STAT5 target gene list used in this study.

**Statistical Analysis**

Statistical analysis was performed using appropriate statistical methods including Student t-test, one- and two-way ANOVA and parametric tests using GraphPad Prism V7.0g (GraphPad Software, Inc.) and JMP version 12.0. The data are shown as the mean with error bars showing ± SEM. Statistical significance indicated as *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.005 \) and ****\( P < 0.001 \).

**Study Approval**

Animals were housed in conventional or pathogen-free conditions, where appropriate, at the mouse facility of Virginia Commonwealth University, in compliance with Institutional Animal Care and Use Committee (IACUC) regulations. All animal experiments were performed according to
protocols approved by the Animal Care and Use Committee of the Virginia Commonwealth University.
Supplemental References

Archer, K.J., and Reese, S.E. (2010). Detection call algorithms for high-throughput gene expression microarray data. Brief Bioinform 11, 244-252.

Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 57, 289-300.

Bolstad, B.M., Collin, F., Simpson, K.M., Irizarry, R.A., and Speed, T.P. (2004). Experimental design and low-level analysis of microarray data. Int Rev Neurobiol 60, 25-58.

de Hoon, M.J., Imoto, S., Nolan, J., and Miyano, S. (2004). Open source clustering software. Bioinformatics 20, 1453-1454.

Dumur, C.I., Nasim, S., Best, A.M., Archer, K.J., Ladd, A.C., Mas, V.R., Wilkinson, D.S., Garrett, C.T., and Ferreira-Gonzalez, A. (2004). Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem 50, 1994-2002.

Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95, 14863-14868.

Gautier, L., Cope, L., Bolstad, B.M., and Irizarry, R.A. (2004). affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315.

Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80.

Harrell, J.C., Dye, W.W., Allred, D.C., Jedlicka, P., Spolstra, N.S., Sartorius, C.A., and Horwitz, K.B. (2006). Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66, 9308-9315.

Irizarry, R.A., Bolstad, B.M., Collin, F., Cope, L.M., Hobbs, B., and Speed, T.P. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15.

Kang, K., Yamaji, D., Yoo, K.H., Robinson, G.W., and Hennighausen, L. (2014). Mammary-Specific Gene Activation Is Defined by Progressive Recruitment of STAT5 during Pregnancy and the Establishment of H3K4me3 Marks. Mol Cell Biol 34, 464-473.

Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
Puchalapalli, M., Zeng, X., Mu, L., Anderson, A., Hix Glickman, L., Zhang, M., Sayyad, M.R., Mosticone Wangensteen, S., Clevenger, C.V., and Koblinski, J.E. (2016). NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice. PLoS One 11, e0163521.

RDevelopmentCoreTeam (2011). R: A Language and Environment for Statistical Computing (Vienna, Austria: The R Foundation for Statistical Computing).

Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J.P. (2006). GenePattern 2.0. Nat Genet 38, 500-501.

Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3.

Strober, W. (2001). Trypan blue exclusion test of cell viability. Curr Protoc Immunol Appendix 3, Appendix 3B.

Volker, S.E., Hedrick, S.E., Feeney, Y.B., and Clevenger, C.V. (2018). Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78, 3877-3887.

Zheng, J., Koblinski, J.E., Dutson, L.V., Feeney, Y.B., and Clevenger, C.V. (2008). Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res 68, 7769-7778.